MOTS-c vs Cotadutide

MOTS-c and Cotadutide are both research peptides studied across multiple applications, but they occupy different positions on the translational spectrum. MOTS-c is a mitochondrial-derived peptide with preclinical evidence supporting roles in insulin sensitivity, exercise adaptation, and aging. Cotadutide is a synthetic dual GLP-1/glucagon receptor agonist that has advanced through Phase II trials for type 2 diabetes, obesity, and NASH. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S rRNA gene (MT-RNR1). Discovered in 2015 by Lee et al. at USC, it acts as a metabolic regulator primarily through AMPK activation. In mouse models, MOTS-c prevents diet-induced obesity and insulin resistance, enhances exercise capacity (old mice ran 2x longer on treadmill tests), and reduces age-related metabolic decline. A modified analog (CB4211) showed good tolerability in a Phase 1 human trial. No clinical trials of native MOTS-c in humans have been completed. Key claims include improved insulin sensitivity and glucose metabolism, exercise mimetic effects, and anti-obesity effects. The evidence base is predominantly preclinical, with human data limited to an analog.

Cotadutide (MEDI0382) is a dual GLP-1/glucagon receptor agonist developed by AstraZeneca (originally MedImmune). It is a once-daily injectable peptide designed to combine GLP-1 receptor-mediated glucose lowering and appetite suppression with glucagon receptor-mediated hepatic fat oxidation and energy expenditure. Phase II trials have been completed in type 2 diabetes, obesity, and NASH/MASH. Development status is uncertain after mixed Phase II results and AstraZeneca portfolio prioritization.

Key claims: Reduces liver fat in NASH/MASH; Improves glycemic control in T2D; Produces weight loss.

Both peptides are studied for metabolic health, but their research contexts differ. MOTS-c is also investigated for anti-aging, reflecting its mitochondrial origin and effects on exercise capacity and age-related decline. Cotadutide is additionally researched for weight management and NASH, consistent with its dual agonist mechanism and clinical development focus. Researchers should consider these distinctions when selecting a peptide for specific metabolic or aging-related models.

MOTS-c: No adverse effects reported in preclinical animal studies. Human tolerability is completely unknown for native MOTS-c (no completed human trials). The modified analog CB4211 showed good tolerability in Phase 1. Cotadutide: Common side effects include nausea, vomiting, diarrhea, and decreased appetite (GLP-1 class effects). GI adverse events are dose-dependent; titration helps manage tolerability. Once-daily dosing may produce more GI side effects than weekly formulations due to peak-trough fluctuations. Researchers should weigh these safety profiles against their experimental endpoints.